Monogenic permanent neonatal diabetes (PNDM) is typically diagnosed within the first 6 months of birth in contrast to polygenic autoimmune type 1 diabetes, which is usually diagnosed later in childhood or in young adults ([@B1],[@B2]). PNDM is both phenotypically and genetically heterogeneous. Most patients present with isolated diabetes, but in some cases diabetes appears in the context of a more complex multisystemic syndrome. Dominant mutations in three genes (*KCNJ11*, *ABCC8*, and *INS*) are the cause of PNDM in ∼50% of cases, and in the majority diabetes is an isolated finding ([@B3],[@B4]). Recessive mutations, autosomal or X-linked, have been described in 10 genes (*ABCC8, GCK, EIF2AK3*, *FOXP3*, *IPF1*, *PTF1A*, *GLIS3*, *SLC2A2*, *SCL19A2*, and *WFS1*). These are rare and often result in extrapancreatic features in addition to neonatal diabetes ([@B3]). The genetic cause remains unknown in up to 40% of patients with PNDM ([@B4]).

From a pathogenetic perspective, a number of different mechanisms can lead to PNDM. Firstly, β-cells may be present but not functional as in patients with activating mutations in *KCNJ11* and *ABCC8*, the genes encoding the two subunits of the ATP-sensitive K^+^ channel (Kir6.2 and SUR1, respectively). Secondly, the number of β-cells may be reduced due to an increased destruction, either by apoptosis (*INS* and *EIF2AK3*) or as a consequence of an autoimmune insult (*FOXP3*). Finally, there may be a reduced number of β-cells as a result of impaired pancreatic development, affecting either the whole pancreas (*IPF1* and *PTF1A*) or endocrine cells (*GLIS3*) specifically ([@B3]).

Pancreatic development is coordinated by a complex interplay of signaling pathways and transcription factors that determine early pancreatic specification as well as the later differentiation of exocrine and endocrine lineages ([@B5],[@B6]). The basic helix-loop-helix (bHLH) transcription factor NEUROD1 (also known as BETA2) plays an important role in the development of the endocrine pancreas. *NEUROD1* expression, along with *NEUROG3* and *INSM1*, specifies the endocrine lineage ([@B7]). *Neurod1*^−^/^−^ mice fail to develop mature islets, leading to ketosis-prone diabetes and death within the first few days of life ([@B8]).

Heterozygous loss-of-function mutations in *NEUROD1* have previously been identified as a very rare cause of maturity-onset diabetes of the young (MODY) and late-onset diabetes in humans, with only five families reported to date ([@B9][@B10][@B11]--[@B12]). We assessed the role of *NEUROD1* in PNDM and describe two unrelated probands with homozygous truncating *NEUROD1* mutations who have PNDM and similar neurological abnormalities.

RESEARCH DESIGN AND METHODS
===========================

This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the local ethics committee, and written informed consent was obtained from the parents or guardians of each patient.

Study population.
-----------------

We studied 44 probands with PNDM diagnosed before 6 months of age, who had been referred to the Molecular Genetics Laboratory at the Peninsula Medical School in Exeter, U.K.. Mutations in *KCNJ11, ABCC8, INS*, and *GCK* had been excluded. The relevant clinical information was obtained from the medical records.

*NEUROD1* gene analysis.
------------------------

Genomic DNA was extracted from peripheral leukocytes using standard procedures. The single coding exon of *NEUROD1* was PCR amplified in three overlapping fragments using specific primers for each amplicon tagged with 5′ M13 tails to allow sequencing to be performed with a universal M13 primer (primers and conditions available upon request). Single-strand sequencing was carried out using standard methods on an ABI 3730 sequencer (Applied Biosystems, Warrington, U.K.). Sequences were compared with the published template (accession no. [NM_002500](NM_002500)) using Mutation Surveyor (version 3.20; SoftGenetics). Sequence variants were tested for their presence in family members whenever DNA was available.

Homozygosity mapping.
---------------------

High-density single nucleotide polymorphism (SNP) genotyping was carried out on the Affymetrix human 10K Xba chip by Medical Solutions Nottingham (formerly GeneService) (Nottingham, U.K.). Processing of genomic DNA was performed in accordance with the Affymetrix protocol. In-house Perl scripts were developed to automatically identify genomic homozygous segments, defined by at least 20 consecutive homozygous SNPs marking a region that exceeded 3 cM ([@B13]).

RESULTS
=======

Molecular genetics.
-------------------

Two novel homozygous mutations in *NEUROD1*, a single base pair duplication (c.364dupG) and a two-base pair CT deletion (c.427_428del), were identified in two unrelated probands. Both mutations result in a frameshift and a premature truncation of the C terminus of the expressed protein (p.Asp122Glyfs\*12 and p.Leu143Alafs\*55, respectively), leading to mutated proteins completely lacking the transactivation domain ([Fig. 1](#F1){ref-type="fig"}). These mutations had not been previously documented and were not present in 200 alleles from healthy unrelated individuals. No mutations were identified in the remaining 42 patients.

![Schematic organization of NEUROD1 protein and effect of the two mutations on its structure. Numbers refer to the amino acids bordering the functional domains. Both mutations result in the generation of a truncated protein lacking the transactivation domain. The abnormal protein sequence between the frameshift and the termination codon is colored in gray.](zdb0091062640001){#F1}

The two homozygous probands inherited the mutation from their heterozygous parents ([Fig. 2](#F2){ref-type="fig"}). In family A with the c.364dupG mutation, parents were known to be first cousins and, consistent with parental consanguinity, SNP genotyping analysis of the proband revealed a total genomic homozygosity value of 6.0% ([@B13]). The mutation-containing homozygous segment was the largest homozygous segment (46.6-Mb long) and spanned 2q31.1--2q36.1 delimited by the SNPs rs726032 to rs724149. In contrast, in family B, the parents of the patient with the homozygous c.427_428del mutation were not known to be related and, in keeping with this, total genomic homozygosity value was very low (0.3%). However, the mutation in both parents was inherited on an extended haplotype of 10.4 Mb between positions Chr2q31.1--32.1 (SNPs rs2884471--rs722385), suggesting that the mutation arose from a single common ancestor.

![Extended pedigrees of the two families showing inheritance of *NEUROD1* mutations (family A, c.364dupG \[*A*\]; family B, c427_428del \[*B*\]). Genotype is shown underneath each symbol; M and N denote mutant and wild-type alleles, respectively. Directly below the genotype is the age of the individual at testing or the age at diagnosis of diabetes if diabetic, followed by the most recent treatment for diabetes. Subjects who were genotyped were tested for diabetes. Squares represent male family members, and circles represent female subjects. Black-filled symbols denote patients with neonatal diabetes, and gray-filled symbols represent patients with later-onset diabetes. A dash denotes information not applicable or not available. An arrow denotes the proband in each family. OHA, oral hypoglycemic agents.](zdb0091062640002){#F2}

Clinical features.
------------------

The two probands were diagnosed with permanent diabetes within the first 2 months of life and had presented with intrauterine growth retardation (birth weights 1,490 and 2,230 g at 34 and 38 weeks of gestation, respectively), reflecting reduced insulin secretion in utero. They had no evidence of pancreatic exocrine dysfunction and normal pancreatic size on abdominal scanning (see supplementary information, available in an online appendix \[<http://diabetes.diabetesjournals.org/cgi/content/full/db10-0011/DC1>\]). In addition to diabetes, they presented with a similar pattern of neurological abnormalities including moderate-to-severe developmental delay, profound sensorineural deafness, and visual impairment due to myopia and diffuse retinal dystrophy. Brain magnetic resonance imaging scans showed severe cerebellar hypoplasia with no other major intracranial abnormalities ([Fig. 3](#F3){ref-type="fig"} and supplementary information). A more detailed clinical description is given in [Table 1](#T1){ref-type="table"}.

![Magnetic resonance imaging of the brain in a proband from family A demonstrating the typical neuroimaging findings of *NEUROD1*-PNDM. *A*: Sagittal T1-weighted image. *B*: Coronal T2-weighted image. There is significant cerebellar hypoplasia, particularly of cerebellar vermis inferiorly. Unusually, the posterior fossa is well formed. Supratentorial midline structures and myelination are normal.](zdb0091062640003){#F3}

###### 

Clinical features of the two patients with homozygous *NEUROD1* mutations

                                                        Case A (c0.364dupG)                                                     Case B (c0.427_428del)
  ----------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------
  Sex                                                   Female                                                                  Female
  Country of origin                                     Pakistan                                                                Hungary
  Parental consanguinity                                Yes (first cousins)                                                     No
  Birth information                                                                                                             
      Gestational age (weeks)                           34                                                                      38
      Birth weight (g)                                  1,490                                                                   2,230
      Birth weight (SDS)                                −2.06                                                                   −1.92
  Diabetes                                                                                                                      
      Age at diagnosis (weeks)                          8                                                                       4
      Blood glucose (mmol/l)                            31.8                                                                    24.0
      Ketosis                                           Yes                                                                     No
      C-peptide                                         N/A                                                                     Undetectable
      Exocrine function                                 Normal                                                                  Normal
      Pancreas size                                     Normal (MRI scan)                                                       Normal (CT scan)
      Current insulin dose (units · kg^−1^ · day^−1^)   1.1                                                                     Not known
  Neurological features                                                                                                         
      Developmental delay                               Yes                                                                     Yes
      Cerebellar hypoplasia                             Severe cerebellar hypoplasia on MRI                                     Severe cerebellar hypoplasia on MRI
      Sensori-neural deafness                           Yes (hearing aids \[80 dB loss\])                                       Yes (hearing aids)
      Visual impairment                                 Severe myopia, diffuse retinal dystrophy (ERG reduced to approx. 25%)   Moderate myopia, pigmental epithelial atrophy and enlarged fovea
      Seizures                                          No epilepsy; two hypoglycemic seizures (at 7 and 15 years)              No epilepsy

CT, computed tomography; ERG, electroretinography; MRI, magnetic resonance imaging; SDS, SD score.

There was limited availability of other family members for genetic and clinical testing. The diabetes status, age of diagnosis, treatment, and genetic testing result of family members are shown in [Fig. 2](#F2){ref-type="fig"}. We assessed glucose tolerance in the four parents of the two probands who were proven heterozygous carriers of the mutations. In family A (c.364dupG mutation), the mother had been diagnosed with type 2 diabetes at 33 years, despite having a normal BMI, and was treated with glicazide. In contrast, the father (also aged 33 years) had normal fasting (4--6 mmol/l) and postprandial (5--7 mmol/l) blood glucose levels on several occasions. In family B (c.427_428del mutation), the mother and father underwent standard oral glucose tolerance tests (aged 33 and 37 years, respectively) that confirmed normal glucose tolerance (6.2 and 4.8 mmol/l, respectively, at 2 h). No heterozygous family members in either family had any developmental delay or neurological features on clinical examination.

DISCUSSION
==========

We report the first two cases of PNDM caused by homozygous mutations in *NEUROD1*. The patients with this novel autosomal recessive syndrome not only had early-onset permanent diabetes but also presented with developmental delay, cerebellar hypoplasia, and hearing and visual impairment. This is the 13th gene in which mutations have been described in patients with permanent neonatal diabetes.

NEUROD1, a tissue-specific member of the bHLH family of transcription factors, is expressed in developing pancreatic islets and in mature β-cells. It forms a heterodimer with the ubiquitous bHLH transcription factor E47 that binds to specific E-box motifs on specific target genes, including *INS*, *GCK*, and *ABCC8*, to regulate their expression ([@B14][@B15]--[@B16]). The two homozygous *NEUROD1* mutations both introduce a frameshift that results in truncated proteins lacking the transactivation domain, which has been shown to be important for the interaction of NEUROD1 with its main coactivator, p300 ([@B17]). These are likely to have no biological activity, as shown previously for a different frameshift mutation (c.616dupC, p.His206Profs\*38) identified in a patient with *NEUROD1*-MODY ([@B9]). The two patients have a remarkably consistent phenotype ([Table 1](#T1){ref-type="table"}), with clinical features in keeping with the known expression and biology of this transcription factor, and this provides further evidence that the homozygous mutations in *NEUROD1* are causative.

Both patients have neonatal diabetes but a normal pancreas on scanning and no evidence of exocrine dysfunction. This is consistent with the central role of NEUROD1 in islet development. Mice lacking *Neurod1* die shortly after birth from severe diabetic ketoacidosis ([@B8]). Histological examination of the Neurod1-deficient pancreas shows an impaired islet morphogenesis with a reduction in the number of endocrine cells---especially β-cells ([@B8]).

In addition to diabetes, our two patients presented with a similar pattern of neurological features, including developmental delay, cerebellar hypoplasia, and visual and hearing impairment. This is in keeping with the abundant expression of *NEUROD1* in the developing and mature nervous system. Interestingly, the initial *Neurod1*-null mice that rapidly died from diabetes had no obvious anatomic and histologic abnormalities of the brain ([@B8]). However, it is possible to explore the role of Neurod1 in the nervous system by rescuing *Neurod1*-null mice either by expressing a transgene encoding the mouse *Neurod1* gene under the insulin promoter ([@B18]) or by crossing the null mutation into a different genetic background to reduce the severity of the diabetes ([@B19]). The rescued *Neurod1*-null mice show a similar neuronal phenotype consisting of impaired balance, ataxic gait, circling, and swaying head movement as a result of impaired cerebellum development ([@B18][@B19]--[@B20]). Furthermore, rescued *Neurod1*-deficient mice have abnormal hearing and vision as a result of severe sensory neuronal defects in the inner ear and neural retina, respectively ([@B20][@B21]--[@B22]). The main feature seen in the mouse that was not present in our patients was epilepsy ([@B19]). The remarkable similarity between the *NEUROD1*-deficient patients and the *Neurod1*-deficient mice ([Table 2](#T2){ref-type="table"}) strongly supports a similar biological role of this transcription factor across species.

###### 

Comparison of the major features seen in *Neurod1*-deficient mice (refs. [@B8] and [@B18][@B19][@B20][@B21]--[@B22]) and *NEUROD1*-deficient patients with homozygous *NEUROD1* mutations

                                Mouse model                                                                                                              Patient features
  ----------------------------- ------------------------------------------------------------------------------------------------------------------------ -----------------------------
  Endocrine pancreas            Early-onset ketosis-prone diabetesFailure of mature islets developmentStriking reduction in both beta and alpha cells    Permanent neonatal diabetes
  Exocrine pancreas             Postnatal-onset acinar cell polarity defects (indirect effect?)                                                          Normal
  Enteroendocrine cells         Lack of secretin- and cholecystokinin-producing cells (remaining enteroendocrine cells normal)                           Not known
  Cerebral cortex               Normal                                                                                                                   Normal
  Dentate gyrus (hippocampus)   Seizures\>95% decrease of granule cells                                                                                  No epilepsy
  Cerebellum                    Severe hypoplasiaImpaired coordination and ataxiaDecrease of granule cells                                               Severe hypoplasiaAtaxia
  Retina                        BlindnessDecreased synapses and loss of outer nuclear layer                                                              MyopiaRetinal dysfunction
  Inner ear                     Deafness and imbalanceShortened cochlear duct, sensory epithelia abnormalities, and degeneration of acoustic ganglions   Sensorineural deafness

Homozygous mutations in *PTF1A*, which encodes another bHLH transcription factor, also cause a syndrome of neonatal diabetes and cerebellar hypoplasia/agenesis ([@B23]). However, in this condition the pancreatic phenotype is not limited to the islets; affected patients have pancreatic hypoplasia/aplasia. In keeping with the islets representing \<1% of the endocrine pancreas, the size of the pancreas was found to be normal in our two patients with homozygous *NEUROD1* mutations. This suggests that shared developmental pathways are important during development in the pancreas and the cerebellum.

Although heterozygous loss-of-function mutations in *NEUROD1* have previously been identified as a very rare cause of diabetes in humans ([@B9][@B10][@B11]--[@B12]), diabetes was present in only one of four heterozygous mutation--carrying parents. Their age at the time of the study ranged from 33 to 39 years and does not exclude the possibility of developing diabetes later in life. In addition, incomplete penetrance has been described in some of the families with *NEUROD1* diabetes ([@B9]). Homozygous mutations in other known MODY genes, namely *GCK* and *IPF1*, have previously been associated with isolated PNDM and isolated pancreatic agenesis, respectively ([@B24],[@B25]). We have shown that homozygous mutations in another MODY gene are also associated with a more severe phenotype of neonatal diabetes.

In conclusion, homozygous mutations in *NEUROD1* constitute a rare novel autosomal recessive cause of neonatal diabetes with severe neurological abnormalities. This confirms the important role that NEUROD1 plays in the development of both the pancreas and the nervous system in humans.
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